CL2017002082A1 - Nuevas proteínas especificas para pioverdina y pioquelina - Google Patents

Nuevas proteínas especificas para pioverdina y pioquelina

Info

Publication number
CL2017002082A1
CL2017002082A1 CL2017002082A CL2017002082A CL2017002082A1 CL 2017002082 A1 CL2017002082 A1 CL 2017002082A1 CL 2017002082 A CL2017002082 A CL 2017002082A CL 2017002082 A CL2017002082 A CL 2017002082A CL 2017002082 A1 CL2017002082 A1 CL 2017002082A1
Authority
CL
Chile
Prior art keywords
muteins
pyoquelin
pioverdine
present description
specific proteins
Prior art date
Application number
CL2017002082A
Other languages
English (en)
Inventor
Jochen Kruip
Carsten Corvey
Heike Stump
Bernhard Calandra
Astrid Rey
Nathalie Karst
Michael Mourez
Laurent Fraisse
Christine Rothe
Andrea Allersdorfer
Alexander Wiedenmann
Marlon Hinner
Bradley Lunde
Kristian Jensen
Martin Hülsmeyer
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CL2017002082A1 publication Critical patent/CL2017002082A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

<p>La presente descripción proporciona muteinas de hNGAL a las que se une un miembro de la familia de pioverdina o pioquelina y que pueden usarse en diversas apticaciones incluyendo aplicaciones farmacéuticas, P01 ejemplo, para inhibir o reducir el crecimiento de P. aeruginosa. La presente descripción también se refiere a métodos para preparar una o más muteinas a las que se une pioverdina o pioquelina descritas en Ia presente memoria asi como a composiciones que comprenden una o más de dichas muteinas. La presente descripción se refiere además a moléculas de ácido nucleico que codifican dichas muteinas y a métodos para (a generacion de dichas muteinas y moléculas de ácido nucleico. Además, Ia solicitud describe usos terapéuticos y/o de diagnóstico de estas muteínas asi como composiciones que comprenden una o más de dichas muteinas.</p>
CL2017002082A 2015-02-18 2017-08-14 Nuevas proteínas especificas para pioverdina y pioquelina CL2017002082A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15305242 2015-02-18

Publications (1)

Publication Number Publication Date
CL2017002082A1 true CL2017002082A1 (es) 2018-04-27

Family

ID=52595246

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002082A CL2017002082A1 (es) 2015-02-18 2017-08-14 Nuevas proteínas especificas para pioverdina y pioquelina

Country Status (28)

Country Link
US (8) US9884898B2 (es)
EP (1) EP3259282A1 (es)
JP (1) JP6843754B2 (es)
KR (1) KR20170116158A (es)
CN (1) CN107660211A (es)
AR (1) AR103714A1 (es)
AU (1) AU2016221816B2 (es)
BR (1) BR112017017530A2 (es)
CA (1) CA2976687A1 (es)
CL (1) CL2017002082A1 (es)
CO (1) CO2017009433A2 (es)
CR (1) CR20170425A (es)
DO (1) DOP2017000191A (es)
EA (1) EA035824B1 (es)
EC (1) ECSP17061751A (es)
GT (1) GT201700184A (es)
HK (1) HK1245293A1 (es)
IL (1) IL254013A0 (es)
MA (1) MA41072A1 (es)
MX (1) MX375049B (es)
PE (1) PE20171652A1 (es)
PH (1) PH12017501473A1 (es)
SG (1) SG11201706621SA (es)
TN (1) TN2017000348A1 (es)
TW (1) TW201636364A (es)
UY (1) UY36561A (es)
WO (1) WO2016131804A1 (es)
ZA (1) ZA201705257B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3660510A3 (en) 2009-12-07 2020-07-08 Pieris Pharmaceuticals GmbH Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target
SG10201912019WA (en) 2014-05-22 2020-02-27 Pieris Pharmaceuticals Gmbh Novel specific-binding polypeptides and uses thereof
AU2016212087B2 (en) 2015-01-28 2019-11-07 Pieris Pharmaceuticals Gmbh Novel proteins specific for angiogenesis
BR112017017530A2 (pt) * 2015-02-18 2018-04-17 Sanofi proteínas específicas para pioverdina e pioquelina
RU2736312C2 (ru) 2015-05-04 2020-11-13 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Белки, специфичные в отношении cd137
AU2016258977C1 (en) 2015-05-04 2022-07-14 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
US10273275B2 (en) 2015-05-18 2019-04-30 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for glypican-3 (GPC3) and methods of use thereof
AU2016262845B2 (en) 2015-05-18 2020-07-23 Pieris Pharmaceuticals Gmbh Anti-cancer fusion polypeptide
EP3115371A1 (en) * 2015-07-07 2017-01-11 Sanofi Fusion molecules
EA035586B1 (ru) 2015-11-30 2020-07-10 Пиерис Острелиа Пти Лтд. Новые антиангиогенные слитые белки
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
WO2018087108A1 (en) * 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
WO2020018807A1 (en) * 2018-07-19 2020-01-23 The Regents Of The University Of Colorado Methods, systems and compositions for the novel use of enterobactin to treat iron deficiency and related anemia
KR20210146999A (ko) 2019-03-29 2021-12-06 피어이스 파마슈티컬즈 게엠베하 리포칼린 뮤테인의 흡입 투여

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
TR200003635T2 (tr) 1998-06-08 2001-04-20 F.Hoffmann-La Roche Ag Peg-IFN-ALFA ve ribavirinin kronik hepatit C tedavisinde kullanılması.
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
JP4469456B2 (ja) * 2000-04-19 2010-05-26 第一三共株式会社 緑膿菌鉄獲得系阻害物質のスクリーニング法
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
US7056702B2 (en) * 2002-12-16 2006-06-06 Kimberly Clark Co Detecting lipocalin
EP2899277A1 (en) 2004-11-26 2015-07-29 Pieris AG Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
JP2009509535A (ja) 2005-09-27 2009-03-12 アムニクス， インコーポレイテッド タンパク様薬剤およびその使用
CA2729322C (en) 2008-06-24 2020-05-26 Technische Universitaet Muenchen Muteins of hngal and related proteins with affinity for a given target
JP2013529907A (ja) * 2010-05-24 2013-07-25 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク Ｎｇａｌタンパク質変異体及びその使用
CN103074303A (zh) * 2012-12-27 2013-05-01 中国人民解放军第三军医大学 产生抗人ngal特异性单克隆抗体的杂交瘤细胞株及其产生的单克隆抗体与应用
CA2891557A1 (en) 2013-03-26 2014-05-22 Pieris Ag Novel specific-binding polypeptides and uses thereof
BR112017017530A2 (pt) * 2015-02-18 2018-04-17 Sanofi proteínas específicas para pioverdina e pioquelina
EP3115371A1 (en) 2015-07-07 2017-01-11 Sanofi Fusion molecules

Also Published As

Publication number Publication date
MX375049B (es) 2025-03-06
HK1245293A1 (zh) 2018-08-24
US10072056B2 (en) 2018-09-11
US20180371037A1 (en) 2018-12-27
MX2017010628A (es) 2017-12-07
PH12017501473A1 (en) 2018-01-29
PE20171652A1 (es) 2017-11-13
WO2016131804A1 (en) 2016-08-25
EA201791841A1 (ru) 2018-01-31
US20180030101A1 (en) 2018-02-01
CN107660211A (zh) 2018-02-02
EP3259282A1 (en) 2017-12-27
IL254013A0 (en) 2017-10-31
MA41072A1 (fr) 2018-10-31
AU2016221816A1 (en) 2017-10-12
SG11201706621SA (en) 2017-09-28
US9884898B2 (en) 2018-02-06
TW201636364A (zh) 2016-10-16
US10065998B2 (en) 2018-09-04
CR20170425A (es) 2017-11-22
DOP2017000191A (es) 2017-09-29
US20180346532A1 (en) 2018-12-06
JP2018506979A (ja) 2018-03-15
ZA201705257B (en) 2019-06-26
US10329334B2 (en) 2019-06-25
UY36561A (es) 2016-09-30
US10118952B2 (en) 2018-11-06
ECSP17061751A (es) 2017-10-31
AU2016221816B2 (en) 2020-07-02
JP6843754B2 (ja) 2021-03-17
US20180037619A1 (en) 2018-02-08
US20180086799A1 (en) 2018-03-29
AR103714A1 (es) 2017-05-31
GT201700184A (es) 2018-10-24
TN2017000348A1 (en) 2019-01-16
EA035824B1 (ru) 2020-08-17
US20180371038A1 (en) 2018-12-27
CA2976687A1 (en) 2016-08-25
BR112017017530A2 (pt) 2018-04-17
KR20170116158A (ko) 2017-10-18
CO2017009433A2 (es) 2017-11-30
US20180037618A1 (en) 2018-02-08
US20170267734A1 (en) 2017-09-21

Similar Documents

Publication Publication Date Title
CL2017002082A1 (es) Nuevas proteínas especificas para pioverdina y pioquelina
CL2017002767A1 (es) Nuevas proteínas específicas para cd137.
MX2017009767A (es) Nuevas proteínas específicas para la angiogénesis.
CL2017002650A1 (es) Compuestos novedosos
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
MX2016002571A (es) Regulador de ph de transduccion.
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CL2018000107A1 (es) Moléculas de anticuerpo que se unen a cd79
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
PY1520796A (es) Composiciones plaguicidas y metodos relacionados
MX385926B (es) Proteínas de fusión de citoquinas.
DOP2016000253A (es) Nuevos compuestos
CO2017000220A2 (es) Moléculas que tienen cierta utilidad pesticida, intermedios, composiciones y procesos relacionados con las mismas
EA201992707A1 (ru) Соединения и их применения для модуляции гемоглобина
CO2017004735A2 (es) Moléculas que tienen utilidad plaguicida e intermediarios, composiciones y procedimientos relacionados con las mismas
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
MX381776B (es) Formulacion acuosa que comprende paracetamol e ibuprofeno.
DOP2016000118A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
BR112014030720A8 (pt) composto, composição farmacêutica e usos de inibidores de fbx03
MX2018002514A (es) Citotoxinas modificadas y su uso terapeutico.
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt